Rakovina Therapeutics Inc.
RKVTF
$0.09
$0.000.11%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 100.05% | 334.64% | 358.32% | 161.25% | 60.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.35% | 269.63% | 187.30% | 104.94% | 57.12% |
| Operating Income | -72.35% | -269.63% | -187.30% | -104.94% | -57.12% |
| Income Before Tax | -74.48% | -251.50% | -172.16% | -99.53% | -53.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -74.48% | -251.50% | -172.16% | -99.53% | -53.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -74.48% | -251.50% | -172.16% | -99.53% | -53.72% |
| EBIT | -72.35% | -269.63% | -187.30% | -104.94% | -57.12% |
| EBITDA | -84.62% | -327.79% | -233.97% | -132.59% | -74.59% |
| EPS Basic | 26.00% | -56.25% | -35.55% | -39.21% | -19.68% |
| Normalized Basic EPS | 26.11% | -56.23% | -35.34% | -37.47% | -19.68% |
| EPS Diluted | 26.00% | -51.08% | -75.13% | -71.45% | -10.86% |
| Normalized Diluted EPS | 26.11% | -56.23% | -35.34% | -37.47% | -19.68% |
| Average Basic Shares Outstanding | 135.85% | 125.00% | 100.86% | 43.36% | 28.45% |
| Average Diluted Shares Outstanding | 135.85% | 125.00% | 100.86% | 43.36% | 28.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |